All In Biotech

Drug Trial Radar · NCT04214197

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

An Open Label, Photo Documentation Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Feb 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Feb 3, 2020

Primary completion

Jul 2021

Study completion Aug 2021

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Jan 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to document the timing of improvement in atopic dermatitis symptoms and severity following the application of crisaborole ointment 2% in patients 2 years or older with mild to moderate atopic dermatitis. Crisaborole ointment 2% will be applied topically twice daily for four weeks and progress will be assessed by photography and patient-reports.

Conditions

  • Atopic Dermatitis

Interventions

  • Crisaborole 2% Top OintDrug

    Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to success (in days) on ISGATime frame: At days 1, 8,15, 21 and 29
  2. Time to success (by week) on ISGATime frame: At days 1, 8,15, 21 and 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MGH Clinical Unit for Research Trials in Skin (CURTIS)

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.